Precision BioSciences reveals initial results from PBGENE-HBV trial. ELIMINATE-B trial investigates multiple ascending doses for chronic Hepatitis B. PBGENE-HBV shows safety and antiviral activity in cohort 1 participants. Participants experienced no serious treatment-related adverse events. HC Wainwright maintains a $60 price target for Precision BioSciences.
iECURE reported positive data for ECUR-506 in OTC deficiency treatment. ECUR-506 shows promising clinical efficacy with good safety profile. BMO upgraded Precision BioSciences, citing positive initial data for ARCUS platform. Potential 100-200% stock upside predicted based on upcoming HBV trial results. DTIL stock rose 25.8% following the positive report.
